WuXi
May 14, 2020
Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost
Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising. The drug limited tumour growth in 43% and shrank tumors in 28% of patients...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
